trending Market Intelligence /marketintelligence/en/news-insights/trending/LOi_sceSrvA2rFe34rhqJw2 content esgSubNav
In This List

Aduro Biotech plans to lay off 51 employees in restructuring

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Aduro Biotech plans to lay off 51 employees in restructuring

Aduro BioTech Inc. said it plans to lay off 51 employees — or about 59% of its workforce — as part of a corporate restructuring.

The Berkeley, Calif.-based biopharmaceutical company also said it plans to minimize its corporate facilities footprint and shut down its European headquarters in Oss, The Netherlands, by the end of the third quarter.

Aduro said the restructuring is expected to extend the company's operating capital.

The company said the planned changes were determined following an analysis of its product candidates targeting the intracellular stimulator of interferon genes, or STING, and a proliferation-inducing ligand — both proteins found in the human body. STING can influence the immune response associated with various autoimmune diseases, a condition where the body's immune system attacks healthy tissue.

The company also conducted an analysis of its cGAS-STING collaboration with Eli Lilly and Co.

"We are creating a more streamlined organization by focusing on generating clinical data and identifying candidates for the cGAS program to bring forward into development," the company said in a news release.